## Mechanisms of ACE Inhibitors in Heart Failure **Key Point:** ACE inhibitors improve survival in heart failure through neurohormonal antagonism and prevention of adverse remodeling — NOT through direct negative inotropy. ### Correct Mechanisms of ACE-I Benefit | Mechanism | Effect | Clinical Outcome | |-----------|--------|------------------| | ↓ Angiotensin II | Vasodilation, ↓ Na retention | Afterload reduction, preload reduction | | ↓ Aldosterone | ↓ Na/H₂O reabsorption, ↓ K loss | Reduced congestion, preserved K⁺ | | ↓ Sympathetic tone | ↓ Catecholamine sensitivity | ↓ HR, ↓ arrhythmia risk | | ↓ Fibrosis | Inhibit TGF-β pathway | Prevent LV remodeling | | ↓ Apoptosis | Anti-inflammatory | Preserve myocyte mass | **High-Yield:** ACE inhibitors work through *neurohormonal modulation*, not through reducing contractility. In fact, by reducing afterload and preload, they allow the failing heart to work more efficiently — contractility may even improve. ### Why Direct Negative Inotropy Is Wrong **Clinical Pearl:** Beta-blockers (like metoprolol in this patient) initially *reduce* contractility but improve survival long-term. ACE-I do the opposite — they improve contractility indirectly by reducing the load on the heart. Direct myocardial depression is NOT a therapeutic goal in HF and is not how ACE-I work. **Warning:** Confusing ACE-I mechanism with beta-blocker mechanism is a common trap. Remember: ACE-I = neurohormonal antagonism; Beta-blockers = negative inotropy + chronotropy (initially harmful, then beneficial). ### Landmark Evidence The CONSENSUS trial (1987) and SOLVD trial (1991) demonstrated ACE-I mortality benefit in systolic HF — mechanism was reduction of neurohormonal activation and prevention of remodeling, not contractility depression [cite:Harrison 21e Ch 297].
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.